AZN EBITDA Growth
AstraZeneca PLC Ordinary Shares · EBITDA Growth
AZN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported22.45%period ending
AZN TTM EBITDA YoY % (22.61% → 22.45%)
Year-over-year change
High-resolution chart · PNG
AZN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 22.4464% | |
| 27.5236% | |
| 28.0724% | |
| 17.1052% | |
| 15.6257% | |
| 12.3977% | |
| 11.065% | |
| 10.7473% | |
| 11.0021% | |
| 26.6188% | |
| 49.1256% | |
| 62.071% | |
| 85.3894% | |
| 60.5491% | |
| 24.0845% | |
| 8.2282% | |
| -19.1002% | |
| -21.3271% | |
| -9.5478% | |
| -4.415% | |
| 12.7086% | |
| 27.3258% | |
| 24.2104% | |
| 15.3953% | |
| 7.5224% | |
| -6.2508% | |
| -5.6243% | |
| 17.5585% | |
| 13.3625% | |
| 15.6115% | |
| 7.27% | |
| -24.3032% | |
| -19.0603% | |
| -10.5401% | |
| -8.8785% | |
| 36.0924% | |
| 30.7718% | |
| 6.6284% | |
| 4.5402% | |
| 0.7644% | |
| 8.832% | |
| 18.7927% | |
| 26.776% | |
| -13.5917% | |
| -26.1448% | |
| -27.1139% | |
| -34.2357% | |
| -25.6628% | |
| -24.6313% | |
| -23.2027% | |
| -22.7466% | |
| -18.3737% | |
| -24.9247% | |
| -29.5814% | |
| -32.0249% | |
| -31.8731% | |
| -9.4036% | |
| -0.9157% | |
| 7.8055% | |
| 16.6466% | |
| -0.9195% | |
| 0.1711% | |
| 4.6409% | |
| 8.318% | |
| 17.952% | |
| 19.6592% | |
| 19.7892% | |
| 14.8239% | |
| 15.2799% | |
| 17.6108% | |
| 18.2312% | |
| 13.8048% | |
| 10.6061% | |
| 4.9545% | |
| 6.2921% | |
| 9.7285% | |
| 11.0058% | |
| 20.5216% | |
| 19.5683% | |
| 195.4531% | |
| 317.0904% | |
| 448.8963% | |
| 682.9% | |
| -42.6843% | |
| -61.4076% | |
| -71.357% | |
| -81.4849% | |
| 3.2719% | |
| 15.9612% | |
| 4.9894% | |
| 9.6027% | |
| -29.7034% | |
| -36.5897% | |
| -32.2837% | |
| -30.7917% | |
| 48.8872% | |
| 51.7255% | |
| 46.2363% | |
| 44.9862% | |
| 63.7133% |